Skip to main content
Karolinska Development logo

Karolinska Development — Investor Relations & Filings

Ticker · KDEV ISIN · SE0002190926 LEI · 54930011ZA52NKO5W681 ST Financial and insurance activities
Open in API
Filings indexed 761 across all filing types
Latest filing 2019-01-29 Regulatory Filings
Country SE Sweden
Listing ST KDEV

About Karolinska Development

https://www.karolinskadevelopment.com/en

Karolinska Development is an investment company specializing in the life sciences sector. It identifies, finances, and supports the creation and growth of companies developing innovative medical technologies and pharmaceuticals. The firm manages a diversified portfolio of biotechnology and medtech ventures, often originating from academic research, with the goal of developing ground-breaking treatments for severe diseases. Karolinska Development leverages its team's expertise in research, development, and commercialization to guide its portfolio companies, providing both capital and strategic support to advance innovations toward the market.

Recent filings

Filing Released Lang Actions
Karolinska Developments portföljbolag Umecrine Cognition presenterar fas 2a resultat för GR3027 vid idiopatisk hypersomni
Regulatory Filings Classification · 1% confidence The document is a press release dated January 29, 2019, announcing clinical trial results (Phase 2a) for a drug candidate (GR3027) developed by a portfolio company (Umecrine Cognition). It details study design, safety, pharmacokinetics, and preliminary efficacy data. The final paragraph states: "*Denna information är sådan information som Karolinska Development AB (publ) (Nasdaq Stockholm: KDEV) är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning. Informationen lämnades genom Viktor Drvota för offentliggörande den 29 januari 2019 klockan 19:05.*" This structure strongly indicates an official regulatory disclosure of material, non-public information. Since it is an announcement of results rather than a full periodic report (like 10-K or IR), and it pertains to clinical development milestones, it fits best under the general 'Regulatory Filings' category (RNS) as a specific announcement of material information required under market abuse regulations, or potentially an Earnings Release (ER) if it were quarterly results, but here it is a specific clinical update. Given the context of clinical trial results disclosure mandated by market rules, RNS is the most appropriate general regulatory filing category for this type of material update that isn't a standard financial report.
2019-01-29 Swedish
Major Shareholding Notification 2018
Major Shareholding Notification Classification · 1% confidence The document details a change in shareholding ('Sell' transaction) by a major holder, The Goldman Sachs Group, Inc., concerning Karolinska Development AB. It specifies the date of the transaction (28/11/2018), the resulting share quantity (0 shares), and the resulting percentage of voting rights (0.00161%). This structure—reporting changes in significant ownership thresholds—is characteristic of a Major Shareholding Notification. The filing type code corresponding to this is MRQ.
2018-12-03 English
SEK 512 miljoner finansiering genomförd i Karolinska Developments portföljbolag Aprea Therapeutics
Capital/Financing Update Classification · 1% confidence The document announces a significant financing round (SEK 512 million) for a portfolio company, Aprea Therapeutics, involving multiple investors. This directly relates to the company's fundraising and capital structure activities. This fits the definition of 'Capital/Financing Update' (CAP). Although it mentions the financial impact will be reported in the Q4 2018 results (published Feb 14, 2019), the core subject of this specific release is the capital injection itself, not the full financial results (ER/IR) or a general regulatory announcement (RNS). The length (4196 chars) is substantial enough to be a primary announcement, not just a brief notice of publication (RPA).
2018-11-30 Swedish
Financing of SEK 512 million secured in Karolinska Development's portfolio company Aprea Therapeutics
Capital/Financing Update Classification · 1% confidence The document announces a significant financing event (SEK 512 million investment) in a portfolio company (Aprea Therapeutics) by an investment consortium led by Redmile Group. This directly relates to the company's investment activities, capital structure changes within its portfolio, and subsequent positive effect on its own earnings. This type of announcement, detailing fundraising and investment structure changes, aligns best with the 'Capital/Financing Update' category. It is not a full annual report (10-K), an earnings release (ER) which focuses on period results, or a management discussion (MDA), but rather a specific corporate finance action.
2018-11-30 English
Major Shareholding Notification 2018
Major Shareholding Notification Classification · 1% confidence The document details a change in shareholding and voting rights for The Goldman Sachs Group, Inc. in Karolinska Development AB. It explicitly states the 'Reason for major shareholding notification Buy' and provides detailed tables showing the 'Before the transaction' and 'After the transaction' quantities, percentages, and the chain of controlling companies. This structure perfectly matches the definition of a Major Shareholding Notification.
2018-11-29 English
Investor Presentation 2018
Investor Presentation Classification · 1% confidence The document text contains detailed financial updates for the 'Tredje kvartalet' (Third Quarter), including net results, earnings per share, portfolio value changes, and significant events occurring during and after the quarter. It also includes a 'VD:s rapport' (CEO's report) summarizing performance and outlook, specifically mentioning Q3 results and upcoming clinical trial data. This structure—quarterly financial highlights, management commentary, and operational updates for a period shorter than a year—is characteristic of an Interim/Quarterly Report. The date 'Solna 13 november 2018' confirms it is a report released shortly after the end of Q3 (September 30th). This aligns perfectly with the definition of an Interim / Quarterly Report (IR).
2018-11-13 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.